Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$84.61M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
878.38%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$80.49M
Q3 2024
Cash
Q3 2024
P/E
-0.8702
Nov 29, 2024 EST
Free Cash Flow
-$38.53M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $17.19M $14.62M $8.035M $949.0K $218.0K
YoY Change 17.62% 81.89% 746.68% 335.32%
% of Gross Profit
Research & Development $64.22M $38.62M $14.99M $7.940M $3.112M
YoY Change 66.28% 157.7% 88.75% 155.14%
% of Gross Profit
Depreciation & Amortization $96.00K $68.00K $15.00K $1.000K $0.00
YoY Change 41.18% 353.33% 1400.0%
% of Gross Profit
Operating Expenses $81.41M $53.24M $23.02M $8.889M $3.330M
YoY Change 52.92% 131.24% 158.99% 166.94%
Operating Profit -$81.41M -$53.24M -$23.02M
YoY Change 52.92% 131.24%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $5.945M $1.830M -$75.00K $0.00
YoY Change 224.86%
% of Operating Profit
Other Income/Expense, Net -$1.000K $1.751M -$3.000K -$647.0K $1.000K
YoY Change -100.06% -58466.67% -99.54% -64800.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$75.47M -$51.49M -$22.96M -$9.611M -$3.329M
YoY Change 46.57% 124.24% 138.89% 188.71%
Income Tax $56.00K $25.00K $3.000K $1.000K
% Of Pretax Income
Net Earnings -$75.52M -$51.51M -$22.96M -$9.611M -$3.330M
YoY Change 46.61% 124.32% 138.92% 188.62%
Net Earnings / Revenue
Basic Earnings Per Share -$2.87 -$2.10 -$1.87
Diluted Earnings Per Share -$2.87 -$2.10 -$993.7K -$415.9K -$144.1K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $122.4M $129.2M $167.4M $4.573M $3.514M
YoY Change -5.25% -22.8% 3560.07% 30.14%
Cash & Equivalents $23.49M
Short-Term Investments $98.95M $106.8M $113.2M
Other Short-Term Assets $1.793M $2.276M $6.958M $103.0K $0.00
YoY Change -21.22% -67.29% 6655.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $124.2M $131.5M $174.3M $4.676M $3.514M
YoY Change -5.52% -24.57% 3628.25% 33.07%
Property, Plant & Equipment $902.0K $1.245M $728.0K $39.00K $0.00
YoY Change -27.55% 71.02% 1766.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.284M $2.560M $302.0K
YoY Change -10.78% 747.68%
Total Long-Term Assets $3.186M $3.805M $1.030M $39.00K $0.00
YoY Change -16.27% 269.42% 2541.03%
Total Assets $127.4M $135.3M $175.4M $4.715M $3.514M
YoY Change
Accounts Payable $2.396M $2.575M $1.208M $618.0K $542.0K
YoY Change -6.95% 113.16% 95.47% 14.02%
Accrued Expenses $14.07M $4.827M $1.199M $1.138M $111.0K
YoY Change 191.55% 302.59% 5.36% 925.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.64M $7.782M $2.550M $1.774M $657.0K
YoY Change 126.64% 205.18% 43.74% 170.02%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $2.500M
YoY Change -100.0%
Other Long-Term Liabilities $325.0K $776.0K $395.0K
YoY Change -58.12% 96.46%
Total Long-Term Liabilities $325.0K $776.0K $395.0K $0.00 $2.500M
YoY Change -58.12% 96.46% -100.0%
Total Liabilities $17.96M $8.558M $2.945M $1.774M $3.157M
YoY Change 109.89% 190.59% 66.01% -43.81%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 26.33M 24.47M 12.29M
Diluted Shares Outstanding 26.33M 24.47M 12.29M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $73.63 Million

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.

Industry: Pharmaceutical Preparations Peers: HERON THERAPEUTICS, INC. /DE/ ALBIREO PHARMA, INC. ALX ONCOLOGY HOLDINGS INC Celularity Inc CytoDyn Inc. EAGLE PHARMACEUTICALS, INC. Ocugen, Inc. Kodiak Sciences Inc. MeiraGTx Holdings plc